EPO Patents = 2

Forward Citations = 12

Loading Chart...

4 inventors (with patents filed for the assignee):

Andrea Marziali (16 out of 51 patents)

Joel Pel (16 out of 39 patents)

Milenko Despotovic (3 out of 3 patents)

4. Milenko Despotovic (1 out of 9 patents)

16 patents: Sort by Forward Citations

1. 12509723 - Methods of sequencing with linked fragments (2025-12-30),

2. 12454719 - Linked ligation (2025-10-28),

3. 12410466 - Linked ligation (2025-09-09),

4. 12378605 - Linked target capture (2025-08-05),

5. 12359251 - Linked target capture (2025-07-15),

6. 12344888 - Linked ligation (2025-07-01),

7. 12338493 - Linked target capture (2025-06-24),

8. 12291747 - Linked target capture (2025-05-06),

9. 12291746 - Methods of sequencing linked fragments (2025-05-06),

10. 12286671 - Linked target capture (2025-04-29),

11. 12247253 - Methods of sequencing linked fragments (2025-03-11),

12. 12098419 - Linked target capture and ligation (2024-09-24),

13. 11905556 - Linked target capture (2024-02-20),

14. 11879151 - Linked ligation (2024-01-23),

15. 11827930 - Methods of sequencing with linked fragments (2023-11-28),

Ncan Genomics, Inc. is a leading biotechnology company specializing in advanced genetic testing and personalized medicine. With a state-of-the-art laboratory and team of expert scientists, we offer innovative solutions for healthcare providers and individuals. Our mission is to empower individuals with actionable genetic information to make informed decisions about their health and well-being.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

16 Patents

#54 in Vancouver

#928 in Canada

#37,723 in the World

Vancouver, Canada

Ncan Genomics, Inc.

Forward Citations = 12

4 inventors:

Andrea Marziali (16 out of 51 patents)

Joel Pel (16 out of 39 patents)

Milenko Despotovic (3 out of 3 patents)

4. Milenko Despotovic (1 out of 9 patents)

Please report any incorrect information to [email protected]

2 patents (EPO):

Please report any incorrect information to [email protected]